Vanguard Group Inc Summit Therapeutics Inc. Transaction History
Vanguard Group Inc
- $5.57 Trillion
- Q4 2024
A detailed history of Vanguard Group Inc transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 11,670,576 shares of SMMT stock, worth $216 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
11,670,576
Previous 10,946,536
6.61%
Holding current value
$216 Million
Previous $240 Million
13.1%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding SMMT
# of Institutions
233Shares Held
83.1MCall Options Held
1.66MPut Options Held
2.56M-
Baker Bros. Advisors LP New York, NY24.4MShares$453 Million4.83% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$146 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.56MShares$122 Million0.01% of portfolio
-
State Street Corp Boston, MA5.6MShares$104 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.2MShares$59.3 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.73B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...